In BRCA1/2 carriers who have been treated for high-grade serous carcinoma of the ovary, fallopian tube, or primary peritoneum, the risk of developing a subsequent breast cancer is lower than reported for unaffected BRCA carriers. The gene discussed is BRCA1; the disease is breast carcinoma.